EU/Austria Clash Over Roche Plant Subsidy
The European Commission has rejected a state aid proposal by Austria toassist in the construction and operation of a plant by Hoffmann-La Roche in Linz for the production of intermediates for the company's antiobesity agent Xenical (orlistat).
The Austrian authorities had proposed funds of 22 million Ecus ($25.1 million) for R&D purposes, but the Commission say that this does not conform with state guidelines for R&D, namely in terms of the need for the aid, the incentive effect and the precompetitive nature of the work proposed. The Commission adds that the incentive effect of the proposed aid is non-existent.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze